Northern Trust’s Theseus Pharmaceuticals, Inc. Common Stock THRX Stock Holding History

Northern Trust’s Portfolio THRX Stock Details THRX Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2024 Q1	–	Sell	-154,580	Closed	-$626K	–	4530
2023 Q4	$626K	Sell	154,580 -2,745	-2%	-$8.38K	﹤0.01%	3464
2023 Q3	$423K	Sell	157,325 -6,790	-4%	-$26.6K	﹤0.01%	3567
2023 Q2	$1.53M	Buy	164,115 +30,655	+23%	+$302K	﹤0.01%	3167
2023 Q1	$1.19M	Buy	133,460 +159	+0.1%	+$1.56K	﹤0.01%	3164
2022 Q4	$664K	Sell	133,301 -254	-0.2%	-$1.49K	﹤0.01%	3406
2022 Q3	$775K	Buy	133,555 +5,495	+4%	+$38.8K	﹤0.01%	3374
2022 Q2	$708K	Buy	128,060 +30,921	+32%	+$255K	﹤0.01%	3435
2022 Q1	$1.12M	Buy	97,139 +255	+0.3%	+$2.73K	﹤0.01%	3369
2021 Q4	$1.23M	Buy	+96,884	New	+$1.46M	﹤0.01%	3461

Northern Trust's THRX Position: Q1 2024 in Review

Northern Trust sold out of Theseus Pharmaceuticals, Inc. Common Stock (THRX) in Q1 2024, closing a stake of 154,580 shares — an estimated $626K sold.

Northern Trust first reported a position in THRX in Q4 2021 and held it in 9 quarters. The position peaked at $1.53M in Q2 2023. 1 fund tracked by Wall St. Rank holds THRX as of Q1 2024.

Northern Trust reported no remaining Theseus Pharmaceuticals, Inc. Common Stock position as of Q1 2024 after selling out during the quarter.
Northern Trust sold 154,580 Theseus Pharmaceuticals, Inc. Common Stock shares in Q1 2024, an estimated $626K.
Northern Trust first reported a position in Theseus Pharmaceuticals, Inc. Common Stock in Q4 2021 and held it in 9 quarters.
Northern Trust's Theseus Pharmaceuticals, Inc. Common Stock position peaked at $1.53M in Q2 2023.
1 fund tracked by Wall St. Rank held Theseus Pharmaceuticals, Inc. Common Stock as of Q1 2024.

Based on Northern Trust's 13F filing for Q1 2024, filed 14 May 2024.